Skip to main content

Advertisement

Fig. 3 | BMC Medicine

Fig. 3

From: Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Fig. 3

Sensitivity to endocrine therapy of subtypes within ER–/PgR+ phenotype. Kaplan–Meier estimates of RFS according to sufficient endocrine therapy or not in the luminal-like (a) and basal-like (b) subgroup in 55 out of the 64 ER–/PgR+/HER2– cases. An endocrine therapy sensitivity score was also calculated according to the subgroups within the ER–/PgR+ group in the 17 cases from cohort 4 (c) and in the 64 cases from cohort 2 (d). The subgroups within the ER–/PgR+ were evaluated by PAM50 in cohort 4 and by immunohistochemistry in the 64 cases. P values of sensitivity score between luminal-like and basal-like are <0.0001 for both sets (Mann–Whitney test). LL, Luminal-like; UN, Undetermined; BL, Basal-like

Back to article page